LUPIN
|
LUPIN Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 71.87 | 42.01 | 9.45 | -33.62 | 26.81 |
| CEPS(Rs) | 98.02 | 68.74 | 29.20 | 3.29 | 46.62 |
| DPS(Rs) | 12.00 | 8.00 | 4.00 | 4.00 | 6.50 |
| Book NAV/Share(Rs) | 374.93 | 311.08 | 270.67 | 263.84 | 300.06 |
| Tax Rate(%) | 17.65 | 20.09 | 37.52 | -9.99 | 26.75 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 14.19 | 11.94 | 6.05 | 0.73 | 9.08 |
| EBIT Margin(%) | 11.59 | 8.61 | 3.48 | -4.14 | 6.43 |
| Pre Tax Margin(%) | 10.80 | 7.63 | 2.52 | -4.62 | 5.93 |
| PAT Margin (%) | 8.89 | 6.10 | 1.57 | -5.09 | 4.34 |
| Cash Profit Margin (%) | 12.04 | 9.87 | 4.67 | 0.50 | 7.48 |
| Performance Ratios | |||||
| ROA(%) | 12.63 | 8.33 | 2.01 | -6.70 | 5.09 |
| ROE(%) | 21.13 | 14.61 | 3.68 | -11.79 | 9.47 |
| ROCE(%) | 21.97 | 16.24 | 6.06 | -7.11 | 9.71 |
| Asset Turnover(x) | 1.42 | 1.37 | 1.28 | 1.32 | 1.17 |
| Sales/Fixed Asset(x) | 1.87 | 1.68 | 1.67 | 1.93 | 1.96 |
| Working Capital/Sales(x) | 4.74 | 6.42 | 8.93 | 7.10 | 5.09 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.54 | 0.59 | 0.60 | 0.52 | 0.51 |
| Receivable days | 50.00 | 52.75 | 56.09 | 53.73 | 64.06 |
| Inventory Days | 51.19 | 54.32 | 58.53 | 53.64 | 48.75 |
| Payable days | 185.58 | 177.49 | 144.07 | 132.55 | 161.68 |
| Valuation Parameters | |||||
| PER(x) | 28.20 | 38.51 | 68.54 | - | 38.08 |
| PCE(x) | 20.67 | 23.54 | 22.19 | 227.04 | 21.90 |
| Price/Book(x) | 5.40 | 5.20 | 2.39 | 2.83 | 3.40 |
| Yield(%) | 0.59 | 0.49 | 0.62 | 0.54 | 0.64 |
| EV/Net Sales(x) | 4.16 | 3.76 | 1.95 | 2.23 | 3.26 |
| EV/Core EBITDA(x) | 17.24 | 19.13 | 17.33 | 85.46 | 18.26 |
| EV/EBIT(x) | 21.92 | 27.50 | 32.73 | -29.81 | 27.16 |
| EV/CE(x) | 4.24 | 4.43 | 1.94 | 1.69 | 2.11 |
| M Cap / Sales | 4.07 | 3.68 | 1.77 | 2.07 | 3.05 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.48 | 20.25 | 1.44 | 8.19 | -1.38 |
| Core EBITDA Growth(%) | 39.39 | 110.03 | 336.33 | -84.13 | -4.77 |
| EBIT Growth(%) | 57.65 | 175.93 | 180.59 | -167.66 | 62.21 |
| PAT Growth(%) | 70.82 | 332.35 | 129.66 | -222.92 | 407.07 |
| EPS Growth(%) | 71.07 | 344.46 | 128.11 | -225.39 | 550.89 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.30 | 0.19 | 0.34 | 0.32 | 0.35 |
| Current Ratio(x) | 1.87 | 1.58 | 1.34 | 1.51 | 1.66 |
| Quick Ratio(x) | 1.26 | 1.00 | 0.86 | 0.95 | 1.17 |
| Interest Cover(x) | 14.62 | 8.77 | 3.61 | -8.61 | 12.92 |
| Total Debt/Mcap(x) | 0.05 | 0.04 | 0.14 | 0.11 | 0.10 |
Compare Financial Ratios of peers of LUPIN
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LUPIN | ₹95,820.7 Cr | 0.5% | 7.2% | 0.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹433,068.0 Cr | -0.2% | 7.1% | 1.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,847.0 Cr | 0.8% | -6% | 4.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹127,985.0 Cr | 1.2% | 6.4% | 13.1% | Stock Analytics | |
| CIPLA | ₹122,826.0 Cr | -0.2% | 1.4% | -0.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,418.0 Cr | 1.2% | 5.8% | 4.2% | Stock Analytics | |
LUPIN Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LUPIN | 0.5% |
7.2% |
0.5% |
| SENSEX | 0% |
2.7% |
6.8% |
You may also like the below Video Courses